Wegovy European Medicines Agency medicine overview
The soft tissue malignancies include myxoid liposarcoma, 157 myxoid malignant fibrous histiocytoma 158 and its allied lesions, low-grade fibromyxoid sarcoma 159, 160 and low-grade myofibroblastic sarcoma, 161 myxoid chondrosarcoma, 158, 162 myxoid peripheral nerve sheath tumors, 139 myxoid rhabdomyosarcoma, 163 malignant myoepithelioma, 164 myxoid synovial sarcoma, 165 myxoid follicular dendritic cell sarcoma, 166 myxoid dermatofibrosarcoma protuberans, 167 metastatic chordoma, and its benign mimic, parachordoma
As an endogenous switch for the control of signaling cascade pathways, elevated expression of GST can alter the balance of regulation of kinase pathways during drug treatment, thereby conferring a potential selective advantage
In clinical studies of GLP-1RA plus SGLT2i combination therapy, the safety profile of the combination therapy was consistent with those of the individual agents, with no unexpected findings [9]